跳至主要内容
临床试验/NCT02952482
NCT02952482已完成不适用

Newborn Screening for Adrenoleukodystrophy

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 45,796 人开始时间: 2016年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
45,796
试验地点
1
主要终点
numbers of newborn with ALD

研究概览

简要总结

To test if the routine newborn screening dried blood spots can be used to test if elevation of C26:0 lysophosphatidylcholine (C26:0-lyso-PC), a status indicating adrenoleukodystrophy (ALD)

详细描述

Parents of newborns will be invited to test if their newborns are affected with ALD. The routine newborn screening dried blood spots sample will be used to test the concentration of C26:0-lyso-PC . If positive of a screening test, further confirmation tests including physical examination and other methodology for ALD confirmation will be provided. Genetic counseling and treatment option will be provided, too.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Days 至 3 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Babies born in Taiwan receive regular newborn screening suggested by Ministry of Heath and Welfare.
  • Parents or Legal Guardian sign in the informed consent form.

排除标准

  • Parents or Legal Guardian do not agree to sign in the informed consent form.

结局指标

主要结局

numbers of newborn with ALD

时间窗: 12 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Newborn Screening for Adrenoleukodystrophy | 临床试验